secwatch.observer — SEC 8-K summary
======================================

Issuer:     Syndax Pharmaceuticals Inc (SNDX)
CIK:        0001395937
Form:       8-K
Filed at:   2023-05-08T23:59:59+00:00
Accession:  0000950170-23-018794
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Syndax Q1 net loss $41.1M; on track for two pivotal readouts and NDA/BLA filings in 2023
--------------------------------------------------------------------------------

- Net loss of $41.1M ($0.59/sh) vs $37.2M ($0.63/sh) YoY; cash $449M as of Mar 31, 2023.
- Topline data from AGAVE-201 (axatilimab in cGVHD) expected mid-2023; BLA filing by end of 2023.
- Topline data from AUGMENT-101 (revumenib in KMT2Ar acute leukemia) expected Q3 2023; NDA filing by end of 2023.
- Alexander Nolte resigned as VP, CAO; CFO Keith Goldan appointed as Principal Accounting Officer.
- Full-year 2023 R&D expense guidance reaffirmed at $160-175M; total op ex $225-240M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1395937/000095017023018794/0000950170-23-018794-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1395937/000095017023018794/sndx-20230505.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-018794

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer